Affiliations: [a] Department of Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China | [b] Division of Respiratory Medicine, Department of Respiration, The Affiliated Drum Tower Hospital of Nanjing University Medical College, Nanjing University Medical School, Nanjing, Jiangsu, China
Correspondence:
[*]
Corresponding author: Li-Yun Miao, Division of Respiratory Medicine, Department of Respiration, The Affiliated Drum Tower Hospital of Nanjing University Medical College, Nanjing University Medical School, 321 Zhongshan Road, Nanjing 210008, Jiangsu, China. Tel.: +86 13813920964; Fax: +86 25 83107169; E-mail:liyunmiao462@163.com
Abstract: BACKGROUND: Chemotherapy-related hepatic dysfunction affected the
prognosis of non-small cell lung cancer (NSCLC). However, predictive factors
of chemotherapy-related hepatic dysfunction remained undefined. OBJECTIVE: To identify the predictive factors for hepatic
dysfunction during cytotoxic chemotherapy in Chinese patients with advanced
NSCLC. METHODS: We retrospectively reviewed the medical records of
patients with advanced NSCLC who received cytotoxic chemotherapy at Division
of Respiratory Medicine, the affiliated Drum Tower Hospital of Nanjing
University, from July 2012 to January 2015. We investigated the incidence of
hepatic dysfunction during chemotherapy and evaluated several clinical
factors that are associated with hepatic dysfunction, including body mass
index (BMI) and high density lipoprotein cholesterol (HDL-C). RESULTS: A total of 116 patients were enrolled in study, 54
patients (46.57%) experienced hepatic dysfunction after receiving
chemotherapy. Multivariate analysis for hepatic dysfunction in patients with
advanced NSCLC showed that hepatic dysfunction was associated with higher
BMI (odds ratio = 4.742, P = 0.001) and lower HDL-C (odds ratio = 3.018, P = 0.019).
Pearson's rank correlation analysis revealed that HDL-C and BMI presented a
negative correlation in patients with hepatic dysfunction (r = -0.487, P < 0.001). CONCLUSIONS: Higher BMI and lower HDL-C levels seem to be good
independent predictive factors for chemotherapy-related hepatic dysfunction
in advanced NSCLC. In addition, a negative correlation was presented between
BMI and HDL-C.
